PHASE I TRIAL OF MINOCYCLINE IN PATIENTS WITH CANCER

这项研究的目的是确定 增加米诺环素的剂量并确定最大剂量 患者可以耐受的米诺环素。这项研究还将评估 米诺环素需要很长时间才能离开患者的身体。米诺环素是 一种经美国食品和药物管理局批准用于 对某些感染的治疗。新的研究表明，它 有能力抑制癌症中某些酶的活性 对肿瘤细胞的生长和扩散起重要作用的细胞。 这些结果表明，米诺环素可能有助于患者的身体停止 或阻止患者癌症的进一步生长。

The purpose of this research study is to determine the side effects of increasing doses of minocycline and to determine the maximum dose of minocycline that patients can tolerate. This study will also assess how long it takes for minocycline to leave the patients body. Minocycline is an antibiotic which is approved by the Food and Drug Administration for the treatment of certain infections. New research has revealed that it has the ability to inhibit the activity of certain enzymes in cancer cells which are important in allowing tumor cells to grow and spread. These results suggest that minocycline may help the patients body to stop or prevent the further growth of the patients cancer.